JP2007501212A - Ｖｅｇｆ受容体型チロシンキナーゼの阻害薬としてのキナゾリン誘導体 - Google Patents

Ｖｅｇｆ受容体型チロシンキナーゼの阻害薬としてのキナゾリン誘導体 Download PDF

Info

Publication number
JP2007501212A
JP2007501212A JP2006522409A JP2006522409A JP2007501212A JP 2007501212 A JP2007501212 A JP 2007501212A JP 2006522409 A JP2006522409 A JP 2006522409A JP 2006522409 A JP2006522409 A JP 2006522409A JP 2007501212 A JP2007501212 A JP 2007501212A
Authority
JP
Japan
Prior art keywords
alkyl
alkanoyl
alkoxy
carbamoyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006522409A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007501212A5 (enExample
Inventor
ヘンネキン，ローラン・フランソワ・アンドレ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2007501212A publication Critical patent/JP2007501212A/ja
Publication of JP2007501212A5 publication Critical patent/JP2007501212A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2006522409A 2003-08-06 2004-08-05 Ｖｅｇｆ受容体型チロシンキナーゼの阻害薬としてのキナゾリン誘導体 Withdrawn JP2007501212A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0318423.1A GB0318423D0 (en) 2003-08-06 2003-08-06 Chemical compounds
PCT/GB2004/003393 WO2005013998A1 (en) 2003-08-06 2004-08-05 Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases

Publications (2)

Publication Number Publication Date
JP2007501212A true JP2007501212A (ja) 2007-01-25
JP2007501212A5 JP2007501212A5 (enExample) 2007-09-06

Family

ID=27839733

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006522409A Withdrawn JP2007501212A (ja) 2003-08-06 2004-08-05 Ｖｅｇｆ受容体型チロシンキナーゼの阻害薬としてのキナゾリン誘導体

Country Status (14)

Country Link
US (1) US20070027145A1 (enExample)
EP (1) EP1653965A1 (enExample)
JP (1) JP2007501212A (enExample)
KR (1) KR20060058781A (enExample)
CN (1) CN1863534A (enExample)
AU (1) AU2004262982A1 (enExample)
BR (1) BRPI0413280A (enExample)
CA (1) CA2534422A1 (enExample)
GB (1) GB0318423D0 (enExample)
IL (1) IL173483A0 (enExample)
MX (1) MXPA06001394A (enExample)
NO (1) NO20060641L (enExample)
WO (1) WO2005013998A1 (enExample)
ZA (1) ZA200601030B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014534975A (ja) * 2011-11-14 2014-12-25 スンシネ ルアケ プハルマ カンパニー リミテッド アミノキナゾリン誘導体及びそれらの塩並びに使用方法
JP2017526668A (ja) * 2014-08-11 2017-09-14 石薬集団中奇制薬技術（石家庄）有限公司 キナゾリン誘導体

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1625555A (zh) * 2002-02-01 2005-06-08 阿斯特拉曾尼卡有限公司 喹唑啉化合物
US7569577B2 (en) 2003-09-16 2009-08-04 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
ATE413389T1 (de) 2004-02-03 2008-11-15 Astrazeneca Ab Chinazolinderivate
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
US7829574B2 (en) 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
WO2010005527A1 (en) 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
KR20120107993A (ko) * 2009-12-15 2012-10-04 뉴롭, 인코포레이티드 신경계 장애의 치료를 위한 화합물
US9854482B2 (en) * 2015-04-21 2017-12-26 International Business Machines Corporation Controlling a delivery of voice communications over a cellular data network or a wireless network based on user's profile
CA3012718A1 (en) 2016-02-08 2017-08-17 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
CN106565681B (zh) * 2016-11-10 2019-07-09 中国医学科学院放射医学研究所 含硝基咪唑基团的苯胺喹唑啉类化合物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (en) * 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
PT885198E (pt) * 1996-03-05 2002-06-28 Astrazeneca Ab Derivados de 4-anilinoquinazolina
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
HK1039126B (en) * 1998-10-08 2005-09-30 阿斯特拉曾尼卡有限公司 Quinazoline derivatives
BRPI0017548B8 (pt) * 1999-02-10 2023-05-02 Astrazeneca Ab Composto
EE05330B1 (et) * 1999-11-05 2010-08-16 Astrazeneca Ab Kinasoliini derivaadid kui VEGF-i inhibiitorid
CN1240688C (zh) * 2000-04-07 2006-02-08 阿斯特拉曾尼卡有限公司 喹唑啉化合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014534975A (ja) * 2011-11-14 2014-12-25 スンシネ ルアケ プハルマ カンパニー リミテッド アミノキナゾリン誘導体及びそれらの塩並びに使用方法
JP2017526668A (ja) * 2014-08-11 2017-09-14 石薬集団中奇制薬技術（石家庄）有限公司 キナゾリン誘導体

Also Published As

Publication number Publication date
AU2004262982A1 (en) 2005-02-17
NO20060641L (no) 2006-05-03
WO2005013998A1 (en) 2005-02-17
IL173483A0 (en) 2006-06-11
GB0318423D0 (en) 2003-09-10
CA2534422A1 (en) 2005-02-17
BRPI0413280A (pt) 2006-10-10
KR20060058781A (ko) 2006-05-30
US20070027145A1 (en) 2007-02-01
ZA200601030B (en) 2007-05-30
EP1653965A1 (en) 2006-05-10
MXPA06001394A (es) 2006-05-19
CN1863534A (zh) 2006-11-15

Similar Documents

Publication Publication Date Title
JP4608215B2 (ja) キナゾリン化合物
US20120046300A1 (en) Quinazoline Derivatives as Angiogenesis Inhibitors
AU2003202094A1 (en) Quinazoline compounds
JP2003530387A (ja) キナゾリン化合物
JP2004505965A (ja) 化合物
JP2007501212A (ja) Ｖｅｇｆ受容体型チロシンキナーゼの阻害薬としてのキナゾリン誘導体
JP2008515961A (ja) 癌に対する使用のためのキナゾリン誘導体
HK1139675A (en) Quinazoline compounds
CN101437810A (zh) 喹唑啉衍生物
HK1070367B (en) Quinazoline compounds
HK1154586A (en) Quinazoline compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070718

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070718

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090730